company background image
MOLN logo

Molecular Partners SWX:MOLN Stock Report

Last Price

CHF 3.24

Market Cap

CHF 119.3m

7D

2.1%

1Y

-8.6%

Updated

11 Apr, 2025

Data

Company Financials +

MOLN Stock Overview

A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. More details

MOLN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Molecular Partners AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Molecular Partners
Historical stock prices
Current Share PriceCHF 3.24
52 Week HighCHF 9.50
52 Week LowCHF 2.70
Beta0.61
1 Month Change-13.62%
3 Month Change-28.82%
1 Year Change-8.62%
3 Year Change-82.40%
5 Year Change-83.15%
Change since IPO-85.56%

Recent News & Updates

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Mar 13
Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Recent updates

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Mar 13
Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Sep 10
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Apr 11
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Jan 09
Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Sep 08
Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Jun 23
Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Aug 31
What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

May 09
Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Dec 26
Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Jun 24
We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability

Mar 09
Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability

Shareholder Returns

MOLNCH BiotechsCH Market
7D2.1%-0.1%-2.9%
1Y-8.6%38.1%-2.9%

Return vs Industry: MOLN underperformed the Swiss Biotechs industry which returned 38.8% over the past year.

Return vs Market: MOLN underperformed the Swiss Market which returned -3.7% over the past year.

Price Volatility

Is MOLN's price volatile compared to industry and market?
MOLN volatility
MOLN Average Weekly Movement8.5%
Biotechs Industry Average Movement8.1%
Market Average Movement4.6%
10% most volatile stocks in CH Market8.5%
10% least volatile stocks in CH Market2.4%

Stable Share Price: MOLN's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: MOLN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
2004159Patrick Amstutzwww.molecularpartners.com

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease.

Molecular Partners AG Fundamentals Summary

How do Molecular Partners's earnings and revenue compare to its market cap?
MOLN fundamental statistics
Market capCHF 119.29m
Earnings (TTM)-CHF 54.04m
Revenue (TTM)CHF 4.97m

24.0x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MOLN income statement (TTM)
RevenueCHF 4.97m
Cost of RevenueCHF 47.50m
Gross Profit-CHF 42.53m
Other ExpensesCHF 11.51m
Earnings-CHF 54.04m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Aug 25, 2025

Earnings per share (EPS)-1.47
Gross Margin-855.81%
Net Profit Margin-1,087.38%
Debt/Equity Ratio0%

How did MOLN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/11 18:08
End of Day Share Price 2025/04/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecular Partners AG is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jo WaltonCredit Suisse
null nullCredit Suisse
Thomas KaufmannCredit Suisse